Wall Street analysts predict that Axsome Therapeutics Inc (NASDAQ:AXSM) will announce earnings of ($0.31) per share for the current quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Axsome Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.33) and the highest estimate coming in at ($0.28). Axsome Therapeutics reported earnings of ($0.32) per share during the same quarter last year, which indicates a positive year-over-year growth rate of 3.1%. The business is expected to issue its next earnings report on Wednesday, August 14th.
According to Zacks, analysts expect that Axsome Therapeutics will report full year earnings of ($1.29) per share for the current fiscal year, with EPS estimates ranging from ($1.37) to ($1.17). For the next fiscal year, analysts anticipate that the business will report earnings of ($1.24) per share, with EPS estimates ranging from ($1.70) to ($0.84). Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side analysts that cover Axsome Therapeutics.
Axsome Therapeutics (NASDAQ:AXSM) last posted its quarterly earnings data on Thursday, May 9th. The company reported ($0.32) EPS for the quarter, missing the consensus estimate of ($0.31) by ($0.01).
In other news, CFO Nick Pizzie purchased 1,920 shares of the business’s stock in a transaction on Tuesday, June 11th. The stock was acquired at an average price of $20.80 per share, for a total transaction of $39,936.00. Following the acquisition, the chief financial officer now directly owns 1,920 shares of the company’s stock, valued at approximately $39,936. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Mark E. Saad purchased 3,500 shares of the business’s stock in a transaction on Thursday, May 23rd. The shares were purchased at an average price of $22.33 per share, with a total value of $78,155.00. Following the acquisition, the director now directly owns 7,002 shares in the company, valued at $156,354.66. The disclosure for this purchase can be found here. Insiders have acquired a total of 10,470 shares of company stock valued at $227,087 in the last 90 days. 27.50% of the stock is currently owned by company insiders.
Institutional investors have recently made changes to their positions in the company. Focused Wealth Management Inc purchased a new position in shares of Axsome Therapeutics in the 1st quarter worth approximately $64,000. Millennium Management LLC acquired a new stake in shares of Axsome Therapeutics during the 4th quarter valued at approximately $871,000. EAM Global Investors LLC acquired a new stake in shares of Axsome Therapeutics during the 1st quarter valued at approximately $1,211,000. Barclays PLC acquired a new stake in shares of Axsome Therapeutics during the 4th quarter valued at approximately $30,000. Finally, BlackRock Inc. lifted its position in shares of Axsome Therapeutics by 14.6% during the 4th quarter. BlackRock Inc. now owns 64,049 shares of the company’s stock valued at $181,000 after acquiring an additional 8,137 shares during the period. Hedge funds and other institutional investors own 44.22% of the company’s stock.
Shares of NASDAQ AXSM traded up $0.44 during trading on Monday, hitting $26.48. The company had a trading volume of 126,999 shares, compared to its average volume of 1,239,678. The company has a 50 day simple moving average of $24.33. The company has a quick ratio of 5.68, a current ratio of 5.68 and a debt-to-equity ratio of 1.08. Axsome Therapeutics has a 12 month low of $1.94 and a 12 month high of $28.00. The company has a market capitalization of $877.05 million, a price-to-earnings ratio of -23.03 and a beta of 2.65.
Axsome Therapeutics Company Profile
Axsome Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing novel therapies for central nervous system (CNS) disorders in the United States. Its product pipeline includes AXS-05, which is in the Phase III clinical trial for the treatment resistant depression; Phase II/III clinical trials in agitation associated with Alzheimer's disease; and Phase II clinical trial for the treatment of smoking cessation, as well as for major depressive disorder.
Further Reading: Liquidity
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Axsome Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.